Eli Lilly Corporate Governance: Board Interlocks and Peptide CDMO Exposure

No. Eli Lilly’s board interlocks do not create hidden commercial, legal, or fiduciary exposure to key peptide Contract Development and Manufacturing Organizations (CDMOs).

A rigorous examination of Eli Lilly and Company’s regulatory filings—specifically its definitive proxy statement (Schedule 14A filed with the SEC on March 20, 2026) and related governance disclosures—demonstrates that Lilly’s board composition is completely separate from the primary merchant peptide manufacturers (such as Bachem, Lonza, PolyPeptide Group, and CordenPharma).

---

1. What the Proxy Disclosures (DEF 14A) Establish

Under Item 1 (Election of Directors) and the Corporate Governance sections of Lilly’s Form DEF 14A filed March 20, 2026:

• Categorical Independence: The Board affirmatively determined that each non-employee director is independent under New York Stock Exchange (NYSE) listing standards and Lilly’s own Standards for Director Independence. Specifically, none of the non-employee directors has had any material commercial, industrial, consulting, or familial relationship with Lilly or its key operational vendors over the past three years.
• Related-Person Transaction Protocols: Lilly maintains a strict written policy governing transactions with related persons. Directors are required to disclose any potential conflict of interest, and the board’s governance guidelines mandate recusal from any board discussions or decisions involving an entity with which a director has an external commercial relationship.
• Absence of CDMO Ties: None of Lilly’s directors or executive officers serve on the boards, executive committees, or advisory councils of commercial pharmaceutical peptide CDMOs.

---

2. Evaluating High-Profile Board Backgrounds

While several directors possess deep industrial supply-chain and biotechnology backgrounds, none translate into concealed exposure to external peptide manufacturing:

• Juan R. Luciano (Lilly Director; Chair of the Directors and Corporate Governance Committee):
  • Affiliation: Chairman and CEO of Archer-Daniels-Midland Company (ADM).
  • Analysis: While ADM is an agricultural processing and nutrition giant with expertise in industrial-scale wet milling and bio-fermentation, it is not an active pharmaceutical ingredient (API) peptide synthesizer. Tirzepatide (the active molecule in Mounjaro and Zepbound) relies on specialized, high-yield solid-phase and liquid-phase chemical peptide synthesis and complex cleaving/purification, an area outside ADM’s operational scope.
• Jon R. Moeller (Lilly Director):
  • Affiliation: Executive Chairman and former CEO of The Procter & Gamble Company.
  • Analysis: Moeller provides board-level oversight on high-volume consumer supply chains, packaging, and retail distribution—capabilities directly relevant to the expansion of LillyDirect, Lilly's direct-to-consumer pharmacy model. P&G has zero footprint in pharmaceutical peptide synthesis or sterile injectable fill-finish CDMO contracting.
• Dr. Carolyn R. Bertozzi (Lilly Director; Science and Technology Committee):
  • Affiliation: Nobel Laureate, Stanford University professor, and director at OmniAb, Inc. (and formerly Alnylam Pharmaceuticals).
  • Analysis: Dr. Bertozzi’s expertise lies in bioorthogonal chemistry and discovery platforms. OmniAb is an antibody discovery engine, and Alnylam is focused on RNA interference (RNAi). Neither business provides commercial contract development or manufacturing services for therapeutic peptides.

---

3. The Structural Reality: Lilly Is In-Sourcing, Not Entangling

The notion that Lilly might rely on hidden, board-level ties to secure peptide capacity misreads Lilly’s fundamental capital allocation strategy.

Rather than relying on entangled external relationships or merchant CDMOs for its long-term survival, Lilly has aggressively verticalized its manufacturing footprint:

1. Massive Capital Deployment: To support the unprecedented global demand for tirzepatide and its next-generation oral and injectable cardiometabolic pipeline (such as orforglipron and retatrutide), Lilly has committed tens of billions of dollars to internal greenfield and brownfield manufacturing facilities across Indiana, North Carolina, Wisconsin, Ireland, and Germany.
2. Arm’s-Length Vendor Contracts: Where Lilly does contract with external CDMOs for intermediate peptide fragments, sterile fill-finish, or autoinjector assembly, these arrangements are conducted via standard, arm's-length commercial procurement agreements. They do not involve board-level equity warrants, joint venture governance seats, or reciprocal directorships.
3. Insulation from Competitor CDMO Bottlenecks: When Novo Holdings moved to acquire Catalent, market scrutiny intensified regarding third-party CDMO dependencies across the GLP-1 class. Lilly’s corporate response was not to seek captive governance ties with remaining independent CDMOs, but rather to accelerate the direct ownership of its physical plants and internalize end-to-end peptide synthesis.

---

Investment Implication

From an investment and corporate governance perspective:

• Zero Board Conflict Risk: There is no hidden pipeline or margin leak originating from dual-fiduciary loyalties or related-party CDMO transfer pricing.
• Pure Operational Execution: Lilly’s capacity risk is fundamentally industrial, not governance-related. Trading at a market capitalization of $1.33 trillion and roughly 48 times earnings, the critical factor for investors is whether Lilly's massive internal capital expenditure delivers commercial batch yield and autoinjector output fast enough to meet its multi-billion-dollar demand backlog—not undisclosed entanglements in the boardroom.

An analysis of Eli Lilly and Company’s definitive proxy statement (Form DEF 14A for the period ended March 20, 2026) and its Annual Report (Form 10-K for the fiscal year ended December 31, 2025) reveals several key board directorships that intersect with the multi-stage supply, clinical development, and high-volume distribution infrastructure supporting Lilly’s cardiometabolic (GLP-1/GIP) franchise.

Scaling peptide therapeutics like tirzepatide (marketed as Mounjaro and Zepbound) to satisfy unprecedented global demand requires far more than traditional small-molecule batch manufacturing. It demands an integrated supply chain spanning upstream biological and chemical inputs, global clinical trial supply coordination, industrial-scale bio-processing, and high-volume consumer device assembly and direct delivery.

The primary outside board seats and executive directorships linking Lilly’s board to these critical nodes include:

---

1. High-Volume Packaging, Logistics, and Consumer Delivery

• The Procter & Gamble Company (NYSE: PG)
  • Lilly Director: Jon R. Moeller (Lilly Director since 2024; member of the Audit and Directors and Corporate Governance Committees).
  • Outside Role: Executive Chairman of Procter & Gamble (2026–present); previously Chairman, President, and Chief Executive Officer (2022–2025) and Chief Financial Officer.
  • Supply-Chain Intersection: The greatest physical bottleneck for GLP-1 therapies has historically been fill-finish operations and the mass manufacturing of single-dose auto-injector pen devices. Concurrently, Lilly has bypassed traditional wholesaler friction by scaling LillyDirect, its direct-to-consumer digital pharmacy and home delivery infrastructure. Moeller brings board-level governance from the global benchmark in consumer packaged goods, high-speed automated packaging, retail logistics, and consumer fulfillment networks. Managing the delivery of tens of millions of temperature-controlled mechanical injector devices per month requires the exact manufacturing velocity and supply-chain discipline practiced at P&G.

---

2. Clinical Supply Chains and Real-World Regulatory Data

• IQVIA Holdings Inc. (NYSE: IQV)
  • Lilly Director: William G. Kaelin, Jr., M.D. (Lilly Director since 2012; Chair of the Science and Technology Committee, member of the Directors and Corporate Governance Committee).
  • Outside Role: Independent Director of IQVIA Holdings Inc.
  • Supply-Chain Intersection: IQVIA is the world’s largest contract research organization (CRO) and healthcare data and logistics provider. Before a drug can flow through commercial channels, its clinical trial supply chain—managing active comparator drugs, patient kits, and global multi-site distribution across dozens of concurrent trials—must function seamlessly. Lilly is actively expanding tirzepatide into cardiovascular risk reduction, obstructive sleep apnea, and metabolic dysfunction-associated steatohepatitis (MASH), alongside Phase 3 pipelines for next-generation multi-agonists (retatrutide and the eloralintide combo). Kaelin’s dual seat connects Lilly to the primary global provider of clinical trial logistics, patient tracking, and post-market pharmacovigilance data.

---

3. Industrial Bio-Processing and Large-Scale Materials

• Archer-Daniels-Midland Company (NYSE: ADM)
  • Lilly Director: Juan R. Luciano (Lilly Director; Chair of the Directors and Corporate Governance Committee).
  • Outside Role: Chairman, President, and Chief Executive Officer of ADM.
  • Supply-Chain Intersection: Peptide synthesis and recombinant DNA expression at the scale required for global cardiometabolic treatment demand vast quantities of high-purity raw materials, chemical precursors, amino acid inputs, and continuous fermentation infrastructure. Luciano’s leadership at one of the world’s largest agricultural processing and bio-refining enterprises provides the board with expertise in commodity-scale biomanufacturing, industrial processing economics, and bulk ingredient supply resilience.

---

4. Upstream Platforms and Molecular Delivery Toolkits

• OmniAb, Inc. (NASDAQ: OABI) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
  • Lilly Director: Carolyn R. Bertozzi, Ph.D. (Lilly Director since 2025; member of the Ethics and Compliance and Science and Technology Committees).
  • Outside Roles: Director of OmniAb, Inc.; recent prior public board member of Alnylam Pharmaceuticals, Inc.
  • Supply-Chain Intersection: While positioned at the discovery end of the supply spectrum, these directorships link Lilly to foundational biological platform technologies:
    • OmniAb operates transgenic animal systems used to discover fully human antibodies and engineered protein formats.
    • Alnylam pioneered liver-targeted RNA interference (RNAi) and advanced oligonucleotide conjugate delivery. As the industry advances beyond standard injectable GLP-1/GIP peptides toward infrequent, long-acting gene silencing (targeting targets like PCSK9, LPA, or ANGPTL3) and complex peptide-antibody or peptide-oligonucleotide conjugates, board exposure to these platforms connects Lilly to critical upstream intellectual property, specialized synthesis techniques, and discovery toolkits.

---

Investment Context

Eli Lilly is trading at premium earnings multiples (around 48x trailing earnings) on expectations that it will continue dominating the global cardiometabolic market while growing 2026 revenue above $90 billion. At this scale, supply-chain execution is not merely an operational detail—it is the governing constraint on the company's return on invested capital (ROIC) and free cash flow conversion.

The composition of Lilly’s board reflects a deliberate cross-section of external governance: securing preeminent medical research insight (Kaelin, Bertozzi), industrial and bioprocessing operational scale (Luciano), and mass-market consumer logistics and packaging discipline (Moeller).